Protocol Ledger

NCT07127822 · Phase II · RECRUITING

Assessing Iparomlimab and Tuvonralimab in Recurrent or Metastatic MSI-H/dMMR Gastric Cancer

Interventional Phase II clinical trial protocol NCT07127822 sponsored by Peking University in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-12-15 Enrollment: 106 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07127822
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)106 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07127822
Protocol FieldVerified Registry Value
NCT IdentifierNCT07127822
Consolidated Lead SponsorPeking University
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment106 participants (ESTIMATED)
Registered Start Date2025-12-15
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI